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Abstract
Acute calculus cholecystitis is a very common disease with several area of uncertainty. The World Society of Emergency
Surgery developed extensive guidelines in order to cover grey areas. The diagnostic criteria, the antimicrobial therapy,
the evaluation of associated common bile duct stones, the identification of “high risk” patients, the surgical timing, the
type of surgery, and the alternatives to surgery are discussed. Moreover the algorithm is proposed: as soon as diagnosis
is made and after the evaluation of choledocholitiasis risk, laparoscopic cholecystectomy should be offered to all patients
exception of those with high risk of morbidity or mortality. These Guidelines must be considered as an adjunctive tool
for decision but they are not substitute of the clinical judgement for the individual patient.
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Background
Gallstones are common and present as acute calculus
cholecystitis (ACC) in 20 % of patients with symptom-
atic disease, with wide variation in severity. In developed
countries, 10–15 % of the adult population is affected by
gallstones. According to the third National Health and
Nutrition Examination Survey, 6.3 million men and 14.2
million women aged 20 to 74 in the United States had
gallbladder disease [1–5]. In Europe, the Multicenter Italian
Study on Cholelithiasis (MICOL) examined nearly 33,000
subjects aged 30 to 69 years in 18 cohorts of 10 Italian re-
gions. The overall incidence of gallstone disease was 18.8 %
in women and 9.5 % in men [6]. However, the prevalence
of gallstone disease varies significantly between ethnicities.
Biliary colic occurs in 1 to 4 % annually [1, 7–9]. ACC oc-
curs in 10 to 20 % of untreated patients [9]. In patients
discharged home without operation after ACC, the prob-
ability of gallstone related events is 14, 19, and 29 % at 6-
weeks, 12 weeks, and at 1 year, respectively. Recurrent
symptoms involve biliary colic in 70 % while biliary tract
obstruction occurs in 24 % and pancreatitis in 6 % [10].
Despite the relevant frequency of ACC, significant contro-
versies remain regarding the diagnosis and management of
ACC. The 2007 and 2013 Tokyo guidelines (TG) attempted
to establish objective parameters for the diagnosis of ACC
[11, 12]. However debates continue in the diagnostic value
of single ultrasound (US) signs, as well as of laboratory
tests. With regard to the treatment of ACC, historically, the
main controversies were around the timing of surgery. The
need for surgery as compared to conservative management
has been less investigated, particularly in high surgical risk
patients. The other major disagreements include: method
and need to diagnose potential associated biliary tree stones
during ACC, treatment options, type of surgery, definition
and management of high surgical risk patients (with clarifi-
cation of the role for cholecystostomy).
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While the TG have certainly improved the understanding
of ACC, some criticisms have followed [13, 14]. Indeed, the
references in the TG are outdated for some recommenda-
tions; the ACC scoring system has not been validated and it
does not distinguish between suspected gallbladder inflam-
mation and systemic signs of ACC. Finally, the conclusions
are not clear because all the different therapeutic options
are available for the same “cholecystitis severity grade”. For
these reasons the World Society of Emergency Surgery
(WSES) decided to convene a consensus conference (CC)
to investigate these controversies and define its guidelines
regarding diagnosis and treatment of ACC.
Material and methods: consensus conference
organizational model
On August 2013 the Scientific Board of the 2nd World
Congress of the World Society of Emergency Surgery
(WSES), endorsed its president, to organize the CC on
ACC in order to develop the WSES Guidelines on this
topic. The WSES President appointed four members to a
Scientific Secretariat, eight members to an Organization
Committee and eight members to a Scientific Committee,
choosing them from the expert affiliates of WSES. Eight
relevant key questions regarding diagnosis and treatment of
ACC (reported in Table 1) were developed to thoroughly
analyse and fully cover the topic. Under the supervision of
the Scientific Secretariat, a bibliographic search related to
these questions was performed by an expert library docu-
mentarist (medical library of Papa Giovanni XXIII Hospital
of Bergamo, Italy), who provided the results of the elec-
tronic search of PubMed and EMBASE through May 2015
without time or language restriction. The key words used
for the electronic search are listed in Table 1. An additional
manual bibliography search was performed by each of the
members of the working groups involved in the analysis of
the above mentioned eight questions. Before the CC, a
number of statements were developed for each of the main
questions, along with the Level of Evidence (LoE) and the
Grade of Recommendation (GoR) for each statement. The
2011 Oxford Classification was used to grade the LoE and
GoR (available at http://www.cebm.net/explanation-2011-
ocebm-levels-evidence/) Provisional statements and their
supporting evidence were then submitted for review to all
the participating members of the CC and to the WSES
board members by email before the CC. Modifications
were performed when necessary based on feedback.
The CC on ACC was held in Jerusalem, Israel, on July
6th, 2015 during the 3rd World Congress of the WSES.
During the first part of the CC, a member of each group
presented each of the statements along with LoE, GoR,
and the literature supporting each statement. Each state-
ment was then voted upon by the audience in terms of
“agree” or “not agree” using an electronic voting system.
The percentage of agreement was recorded immediately;
in case of disagreement greater than 30 %, the statement
was modified after discussion. Furthermore, comments
for each statement were collected; the results of vote are
available in Appendix 1. Before the second part of the CC,
the president and representatives from the Organization
Committee, Scientific Committee and Scientific Secre-
tariat modified the statements according to the findings
of the first session of the CC. The revised statements were
then presented again to the audience. During the CC, a
comprehensive algorithm for the treatment of ACC was
developed based on the results of the first session of the
CC and voted upon for definitive approval (Fig. 1). Simple
Table 1 Key questions and key words used to develop the Consensus Conference on Acute Calculous Cholecystitis (ACC)
Key questions Key words
1) Diagnosis of ACC: investigations. Acute calculous cholecystitis Diagnosis, Ultrasound, Gallstones disease
diagnosis.
2) Treatment of ACC: best options. Gallstones Dissolution, No-surgery gallstones, Extra-corporeal shock
wave lithotripsy, Acute calculous cholecystitis, Gallstone disease,
Management Gallstones, Endoscopy, Gallstone removal, Observation
gallstones.
3) Antibiotic therapy for ACC. Antibiotics,Acute calculous cholecystitis, Gallstone disease, Management
Gallstones.
4) Patient selection for surgery: risk stratification i.e. definition of high
risk patients
Acute calculous cholecystitis, Gallstone disease, Surgical risk score,
High risk patient, old patient, PPossum score, Apache score
5) Timing for surgery for ACC Acute calculous cholecystitis, acute cholecystitis
6) Type of surgery for ACC Acute calculous cholecystitis, Surgery, Laparoscopy, Laparotomy,
Cholecystectomy, Partial cholecystectomy, Subtotal cholecystectomy,
Cirrhosis, Pregnancy
7) Associated common bile duct stone: suspicion and
diagnosis at the presentation
common bile duct stone; choledocholthiasis; endoscopic ultrasound,
MRCP, ERCP,
8) Alternative treatments for high risk patients Acute calculous cholecystitis, Surgery, Gallbladder Drainage,
Percutaneous gallbladder drainage, Cholecystostomy, High Risk Patient
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statements along with their LoE and GoR are available in
Appendix 2. Meanwhile all statements are reported in the
following Results section, subdivided by each of the
eight questions, with the relative discussion and sup-
portive evidence.
These Guidelines must be considered as an adjunctive
tool for decision but they are not substitute of the clinical
judgement for the individual patient.
Results
Diagnosis: investigations
Although ACC is a common disease encountered in the
Emergency Department, its diagnosis remains a major
challenge. Different diagnostic criteria have been re-
ported in the literature as indicated in the development
of the TG [12]. Evidence of an inflamed gallbladder con-
taining stones is the cornerstone for an appropriate diag-
nosis. The diagnosis of ACC is based on clinical findings,
laboratory data, and imaging studies.
Statement 1.1 There is no single clinical or laboratory
finding with sufficient diagnostic accuracy to establish or
exclude acute cholecystitis (LoE 2 GoR B). Combination of
detailed history, complete clinical examination, and
laboratory tests may strongly support the diagnosis of ACC
(LoE 4 GoR C)
A systematic review and meta-analysis of the role of dif-
ferent clinical signs and bedside tests in the diagnosis of
ACC included 17 studies in which quantitative assess-
ment of diagnostic values of clinical tests were reported
[15]. Twelve variables related to history and clinical
examination, 5 variables related to basic laboratory tests,
and one variable which was a combination of a clinical
sign and a laboratory test were tested in a cohort of pa-
tients with abdominal pain or suspected acute cholecyst-
itis. Results showed that with the exception of Murphy’s
sign, none of the summary positive likelihood ratios (LR)
of the clinical test was higher than 1.6 and none of the
summary negative LR was less than 0.4. Murphy’s sign
had a positive LR of 2.8 (CI 95 % 0.8 to 8.6) and a nega-
tive LR of 0.5 (CI 95 % 0.2 to 1) but the 95 % CI in-
cluded the value 1. Although the study was classified as
one of high quality according to the Oxford classifica-
tion, it presents some limitations. The study did not re-
port the proportion of patients with abdominal pain and
the proportion of patients with suspected acute chole-
cystitis. Although LR is robust to assess the prevalence,
the inclusion of patients with abdominal pain together
with patients having suspicion of acute cholecystitis,
may be a source of heterogeneity since different pre-test
probabilities may be associated with each, modifying the
LRs values as a result. Furthermore, reference standards
for the definitive diagnosis of acute cholecystitis varied
in different studies; this might introduce further bias in
the results due to inadequate reference standards. Finally,
both ACC and acute acalculous cholecystitis had been in-
cluded as target condition in this review; the results may
have been different if ACC alone had been included as the
target condition. In a different prospective diagnostic
study, findings from history, clinical examination, and
Fig. 1 Comprehensive algorithm for the treatment of Acute Calculous Cholecystitis. ACC: acute calculous cholecystitis; CBD: common bile duct;
DLC: delayed laparoscopic cholecystectomy; ELC: early laparoscopic cholecystectomy; ERCP endoscopic retrograde cholangiopancreateography;
EUS: endoscopic ultrasound; IOC: intraoperative cholangiography; LUS: laparoscopic ultrasound; MRCP magnetic resonance cholangiopancreatography
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laboratory tests were evaluated in a large cohort of patients
complaining abdominal pain [16]. The diagnostic accuracy
of a total of 22 variables from the history or clinical symp-
toms, 15 signs from clinical examinations, and two labora-
tory tests were evaluated with a reported positive LR of
25.7 and a negative LR of 0.24. The diagnosis was based on
the combination of clinical tests without providing details
on how such clinical tests had been combined. The study
may have a lower strength of evidence, but it refers to a
large prospective study including more than 1300 patients.
Statement 1.2 Abdominal ultrasound (AUS) is the preferred
initial imaging technique for patients who are clinically
suspected to have ACC because of its lower cost, better
availability, lack of invasiveness, and high accuracy for
gallbladder stones(LoE 2 GoR B)
Widespread availability, lack of invasiveness, lack of ex-
posure to ionizing radiation, and a short period of exam-
ination are the characteristics that make AUS the first
choice imaging investigation for the diagnosis of ACC
[17]. To reach the diagnosis of ACC, two conditions
must be satisfied: the presence of gallbladder stones and
presence of inflammatory changes in the gallbladder
wall. There is no doubt that AUS is the best available in-
vestigation for the first condition. A meta-analysis by
Shea strongly supports this statement. Pooled sensitivity
and specificity of AUS in the diagnosis of gallstones were
84 % (95 % CI: 84–92 %) and 99 % (95 % CI: 99–100 %)
respectively based on diagnostic accuracy data reported
in three studies [18].
Statement 1.3 AUS exploration is a fairly reliable
investigation method but its sensitivity and specificity for
diagnosing ACC is relatively low according to the adopted
AUS criteria (LoE 3 GoRC)
Diagnostic performance of AUS in the diagnosis of in-
flammation of the gallbladder is not as good as its per-
formance in the diagnosis of gallstones, as indicated in a
recent meta-analysis [17]. The meta-analysis was based
on the results of 26 studies including a total of 2847 pa-
tients. The sensitivity in individual studies ranged from
50 to 100 % and specificity from 33 to 100 %; indicating
some heterogeneity in the diagnostic performance of
AUS. Summary sensitivity was 81 % (95 % CI: 75 to
87 %) and summary specificity was 83 % (95 % CI: 74 to
89 %). However strong heterogeneity was indicated by the
inconsistency index, which was reported to be 80 % for
sensitivity and 89 % for sensitivity. The review authors have
also highlighted that 14 different definitions of positive
AUS had been reported in 26 studies; the heterogeneity ex-
ploration was however reported to be inconclusive. The
quality of studies was not reported to allow a firm conclu-
sion. Two cross-sectional diagnostic accuracy studies of
high quality according to the Oxford classification have
been published [19, 20]. The criteria for patient selection,
diagnostic criteria, reference method, and timing from
diagnosis to reference method were sound and well de-
scribed similarly in both studies. In the study by Hwang et
al. [19] which included 107 patients, a sensitivity of 54 %
(95 % CI: not reported) and a specificity of 81 % (95 % CI:
not reported) were reported by using the combination of
sonographic Murphy sign, gallbladder wall thickening
greater than 3 mm, peri-cholecystitc fluid collection as
major criteria and hepatic biliary dilation and gallbladder
hydrops as minor criteria. In the study by Borzellino et al
[20] which included 186 patients, diagnostic criteria were
assessed using a multivariate analysis. Following the multi-
variate analysis, distension of the gallbladder, wall oedema,
and peri-cholecystic fluid collection were adopted as the
criteria for the presence of ACC. The presence of at least
one of these three criteria on AUS resulted in a sensitivity
of 83.7 % (95 % CI: 75.1 to 89.7 %) and specificity of 47.7 %
(95 % CI: 37.6 to 58 %). It appears therefore that AUS may
be of limited utility to diagnose or exclude the diagnosis of
acute cholecystitis according to the used ultrasound
criteria.
Statement 1.4 Evidence on the diagnostic accuracy of
computed tomography (CT) is scarce. While diagnostic
accuracy of magnetic resonance imaging (MRI) might be
comparable to that of AUS, insufficient data are available
to support it. Hepatobiliary iminodiacetic acid scan (HIDA
scan) has the highest sensitivity and specificity for acute
cholecystitis, although its scarce availability, long time
required to perform the test, and exposure to ionizing
radiation limit its use (LoE 2 GoRB)
Because of the poor diagnostic performance of AUS in the
diagnosis of ACC, diagnostic accuracy of other imaging
modalities must be assessed. A meta-analysis by Kieiwiet
et al included studies on CT, MRI, and HIDA in addition
to those on AUS [17]. Data on diagnostic accuracy of CT
is limited. Kieiwiet et al identified only one study including
49 patients. CT findings of acute cholecystitis included
gallbladder distension (41 %), gallbladder wall thickening
(59 %), peri-cholecystic fat density (52 %), peri-cholecystic
fluid collection (31 %), sub-serosal oedema (31 %) and
high gallbladder bile attenuation (24 %) [21]. Thus, there
is no single CT feature which is useful in the diagnosis of
ACC. Furthermore, the ionizing radiation to which pa-
tients are exposed is an issue. CT is therefore usually indi-
cated when sonography is non-diagnostic or patients have
confusing signs and symptoms [22]. Kieiwiet et al included
three studies on MRI including a total of 131 patients
[17]. Summary sensitivity was 85 % (95 % CI: 66 to 95 %)
and specificity was 81 % (95 % CI: 69 to 90 %). There was
substantial heterogeneity for sensitivity (I2 = 65 %) and no
heterogeneity for specificity (I2 = 0 %). In a head-to-head
comparison, diagnostic accuracy of MRI was comparable
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with that of AUS. The comparison was however based on
two studies including only 59 patients; therefore, the
strength of evidence is low. Kieiwiet et al included 40
studies with a total of 4090 patients undergoing HIDA
scan. Summary sensitivity was 96 % (95 % CI: 94 to 97 %)
and specificity 90 % (95 % CI: 86 to 93 %) with no statisti-
cally significant heterogeneity for sensitivity (I2 = 18 %)
but a significant heterogeneity for specificity (I2 = 76). In a
head-to-head comparison of HIDA with AUS based on 11
studies including a total of 1199 patients, HIDA proved to
have better diagnostic accuracy than AUS. The summary
sensitivity of HIDA versus AUS was 94 % (95 % CI: 90 to
97 %) and 80 % (95 % CI: 71 to 87 %) respectively with a P
value < 0.001. The summary specificity of HIDA versus
AUS was 89 % (95 % CI: 84 to 92 %) and 75 % (95 % CI:
67 to 82 %) respectively with P value < 0.001. As reported
in the literature [23] and highlighted by Kieiwiet et al [17],
limitation of the information about the biliary tract, the
lack of availability of HIDA, and an examination time of
several hours strongly shrink the use of HIDA in clinical
practice.
Statement 1.5 Combining clinical, laboratory and imaging
investigations is recommended, although the best
combination is not yet known (LoE 4 GoRC)
Combining clinical and AUS findings may improve the
diagnostic accuracy; however, studies that report results
related to some clinical and imaging combination are
few. Hwang et al. [19] reported a 74 % sensitivity and
62 % specificity by combining positive Murphy sign, ele-
vated neutrophil count, and positive AUS. It is interesting
to note that within this study, the sensitivity of elevated
neutrophil count alone was 79 %; therefore higher than
the 74 % sensitivity of combined clinical, laboratory test,
and AUS signs. Furthermore, specificity of AUS alone was
81 % which was higher than 62 % reported when com-
bined clinical, laboratory, and AUS findings were analysed.
Another study reported 97 % sensitivity and 76 % spe-
cificity by combining C-reactive protein (CRP) and AUS.
However, based on the inclusion criteria, generalisability
of findings may be an issue in applying the findings to
routine clinical practice [24].
The study of Yokoe et al evaluated the Tokyo guide-
lines criteria and found a sensitivity of 91.2 % and a spe-
cificity of 96.9 % of these guidelines in the diagnosis of
ACC [12]. Different clinical, laboratory, and imaging
findings are combined in the Tokyo guidelines, giving a
larger probability to reach the diagnosis. However, the
different combinations were not defined in this report.
As previously stated, generalisability of these findings to
routine clinical practice may be problematic because of
the inclusion criteria used in this study.
A full clinical examination should be performed and
recorded. This should be combined with laboratory tests
for inflammation and AUS. In case of uncertainty in
AUS imaging but with a clinical suspicion of ACC, there
is no definitive evidence on whether to perform a high
cost although highly accurate investigation or to treat
the patient empirically as if he or she had ACC.
Treatment: best options
Statement 2.1 There is no role for gallstones dissolution,
drugs or extra-corporeal shock wave lithotripsy (ESWL) or a
combination in the setting of ACC (LoE 2 GoR B)
The opportunity to dissolve gallstones by medication or
break them by ESWL, or combination of both, instead
of mechanical removal, has never been tested in the set-
ting of ACC. Strict selection is required to obtain satisfac-
tory results from these therapeutic options: less than
5 mm stone, single stone, cholesterol gallstones, functional
gallbladder, and integrity of gallbladder wall when apply-
ing external wave to the gallbladder [25]. The rate of
recurrence after ESWL is 30 to 50 % at 5 years [26]. Urso-
deoxycholic acid was ineffective in a large randomized,
double-blind, placebo-controlled trial in patients waiting
for elective cholecystectomy in the setting of biliary colic
[27]. After gallstone disappearance, the persistence of the
same pathogenic factors that induced gallstone formation
is primarily responsible for their recurrence after non-
surgical treatments of gallstones [28].
Statement 2.2 Since there are no reports on surgical
gallstone removal in the setting of ACC, surgery in the form
of cholecystectomy remains the main option (LoE 4 GoR C)
The opportunity to remove the gallstones in a different
way than cholecystectomy has never been tested in the
acute setting and the report of this technique are very few.
In 2013 Yong et al published the results of 316 consecu-
tive laparoscopic gallbladder-preserving cholelithotomy.
The simultaneous use of a choledochoscope to assess the
gallbladder clearance appears to drastically reduce the rate
of recurrence to 15 % compared to 70 % in the early re-
ports of the 1980’s. The required main patient selection
criteria is the functioning gallbladder; this condition is not
present in ACC [29].
Statement 2.3 Surgery is superior to observation of ACC in
the clinical outcome and shows some cost-effectiveness
advantages due to the gallstone-related complications and
to the high rate of readmission and surgery in the observation
group (LoE 3 GoR C)
We found only one prospective randomized study com-
paring observation to surgery after ACC, published in
2011 by Shmidt [30]. The population size was 33 pa-
tients assigned to observation versus 31 assigned to sur-
gery. After an average follow up period of 14 years, 33 %
(11 patients) in the observation experienced relapse of
gallstones disease (8/11: ACC) and all required surgery.
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After five years the relapse of symptoms was described as
negligible. Despite the value of a long follow-up, the study
is underpowered as recognized by the authors themselves.
Furthermore, of the eligible patients, 41.3 % were excluded
for unknown reasons and the randomization methods
were not reported either. Clinical Evidence in 2014 rated
this study as moderate/low quality [31]. On the basis of
the Shmidt study on ACC and a RCT on symptomatic but
uncomplicated gallstone disease [32], Brazzelli et al. pro-
duced a clinical and cost-effectiveness analysis, comparing
surgery to observation, using an UK based economic
model. They found that patients randomized to observa-
tion experienced a higher rate of gallstone-related compli-
cations (14 % versus 2 %) when compared to surgical
group; this happened more frequently in patients with
ACC than in those with biliary colic only. From the eco-
nomic point of view, the frequency of surgery in the ob-
servational group (with the need for readmission) slightly
favoured surgery. The authors concluded with words of
caution because the number of patients was small. In
addition, not all aspects were analysed (e.g. abdominal
pain in the long term follow up in patients underwent
surgery, pain medications cost in the observational group
patients, number of visit to the General Practitioner in
both groups for biliary related symptoms, etc.) [33, 34].
Statement 2.4 Antibiotics should be suggested as
supportive care; they are effective in treating the first
episode of ACC but a high rate of relapse can be expected.
Surgery is more effective than antibiotics alone in the
treatment of ACC. (LoE 2 GoR C)
Although ACC is an inflammatory process at the begin-
ning, a secondary infection can occur in the case of con-
tinuous bile stasis due to cystic duct occlusion by calculus
and oedema, which can lead to sepsis. While many clini-
cians advocate routine administration of antibiotics in all
patients diagnosed with acute cholecystitis, others restrict
the antibiotics to patients likely to develop sepsis on the
basis of clinical, laboratory, and imaging findings [35].
As a consequence, antibiotics constitute the primary
therapy in patients undergoing delayed surgery or ob-
servation. In a meta-analysis including 9 RCT on early
or delayed cholecystectomy, Papi et al. reported that of
503 patients in the delayed group, 9.3 % experienced a
primary failure of antibiotics and supportive therapy
and almost 15 % who initially responded suffered recur-
rences. The rate of unplanned surgery was 26.5 % and a
total of 23 % had a failure of conservative treatment
[36]. Similar results were reported later in the Cochrane
review including only laparoscopic cholecystectomy by
Gurusamy in 2013. Approximately, 18.3 % of patients
had relapse of symptoms during the waiting period
when treated by antibiotics and delayed laparoscopic
cholecystectomy for ACC [37]. In 2012 de Mestral et al.
published a Ontario-Canada population-based analysis
between 2004 and 2011. They collected 25,397 patients
with ACC. About 41 % of these patients were not oper-
ated at the index admission. Gallstone-related events
were measured at 6 weeks, 12 weeks and at 1 year. The
respective rates were 14, 19 and 29 %. Pancreatitis and
common biliary tract obstruction accounted for 30 % of
these events. Gallstone-related events were more frequent
in patients aged between 18 and 34 years old [10].
Statement 2.5 Cholecystectomy is the gold standard for
treatment of ACC (LoE 3 GoR C)
Statement 2.6 If surgery is not available, medications such
as antibiotics and analgesic should be prescribed and the
patients should be referred to a surgical center (depending
upon the general condition) due to the high rate of
gallstone-related events (LoE 5 GoR D)
Non-surgical options (such as gallbladder drainage) can
be considered in surgical high risk patients. The role
of non-surgical options will be analysed in a different
section.
Antibiotic therapy
Therapy with appropriate antimicrobial agents is an im-
portant component in the management of patients with
ACC [38, 39]. Antibiotics are always recommended in
complicated cholecystitis and in delayed management of
uncomplicated cholecystitis.
Statement 3.1 Patients with uncomplicated cholecystitis
can be treated without post-operative antibiotics when
the focus of infection is controlled by cholecystectomy
(LoE 1 GoR B)
In a recently published prospective randomised controlled
trial [40], a total of 414 patients treated at 17 medical
French centres for grade I or II ACC and who received 2 g
of amoxicillin plus clavulanic acid three times a day and
once at the time of surgery were randomized after surgery
to an open-label, non-inferiority, randomized clinical trial
between May 2010 and August 2012. Patients were ran-
domized to either no antibiotics after surgery or continu-
ation with the preoperative antibiotic regimen three times
daily for 5 days. An imputed intention-to-treat analysis of
the 414 patients showed that the postoperative infection
rates were 17 % (35/207) in the non-treatment group and
15 % (31/207) in the antibiotic group (absolute difference,
1.93 %; 95 % CI, -8.98 to 5.12 %). In the per-protocol ana-
lysis, which involved 338 patients, the corresponding rates
were both 13 % (absolute difference, 0.3 %; 95 % CI, -5.0 to
6.3 %). Among patients with mild or ACC who received
preoperative and intra-operative antibiotics, lack of postop-
erative treatment with amoxicillin plus clavulanic acid did
not result in a greater incidence of postoperative infections.
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Statement 3.2 In complicated acute cholecystitis, the
antimicrobial regimens depend on presumed pathogens
involved and risk factors for major resistance patterns
(LoE 3 GoR B)
The principles of empiric antibiotic treatment should be
defined according to the most frequently isolated microbes,
always taking into consideration the local trend of anti-
biotic resistance. Organisms most often isolated in biliary
infections are the gram-negative aerobes, Escherichia coli
and Klebsiella pneumonia and anaerobes, especially Bac-
teroides fragilis [41, 42]. Pathogenicity of Enterococci in
biliary tract infections remains unclear and specific cover-
age against these microorganisms is not routinely sug-
gested for community-acquired biliary infections [43]. For
selected immunosuppressed patients, i.e. those with hep-
atic transplantation, enterococcal infection should always
be presumed and treated [44]. The main antimicrobial
resistance is due to extended spectrum beta-lactamase
(ESBL) producing Enterobacteriaceae. It is found fre-
quently in community acquired infections in patients
with co-morbidities requiring frequent exposure to
antibiotic treatments [41, 42]. Health care-related infec-
tions are commonly caused by more resistant strains.
For these infections, complex regimens with broader
spectra are recommended as adequate empiric therapy
appears to be a crucial factor affecting postoperative
complications and mortality rates, especially in critic-
ally ill patients [44]. Although there are no clinical or
experimental data to support the use of antibiotics with
biliary penetration for these patients, the efficacy of an-
tibiotics in the treatment of biliary infections may de-
pend on effective biliary antibiotic concentrations too.
However, in patients with obstructed bile ducts, the biliary
penetration of antibiotics may be poor and effective biliary
concentrations are reached only in a minority of patients
[45]. Antibiotics biliary penetration ability (indicated as
the ratio of bile to serum concentrations) are listed in
Table 2 [46].
The choice of the antimicrobial regimen may be prob-
lematic in the management of critically ill patients with
ACC. In patients with severe sepsis or septic shock of
abdominal origin, early correct empirical antimicrobial
therapy has a significant impact on the outcome [47]. In
a prospective observational study involving 180 consecu-
tive patients with secondary generalized peritonitis, Riché
et al. [48] demonstrated a significantly higher mortality
rate in septic shock than in those without septic shock
(35 versus 8 %).
Recent international guidelines for the management of
severe sepsis and septic shock (Surviving Sepsis Campaign)
[49] recommend broad-spectrum intravenous antibiotics
with good penetration into the presumed site of infection
within the first hour. In the event of biliary sepsis, drug
pharmacokinetics may be altered significantly in patients
with severe sepsis and septic shock. Dosage of antibiotics
should be reassessed daily, based on both the pathophysio-
logical status of the patient and the pharmacokinetic prop-
erties of the employed antibiotics [50].
Statement 3.3 The results of microbiological analysis are
helpful in designing targeted therapeutic strategies for
individual patients to customize antibiotic treatment and
ensure adequate antimicrobial coverage in patients with
complicated cholecystitis and at high risk for antimicrobial
resistance. (LoE 3 GoR C)
Identifying the causative organism(s) is an essential step in
the management of ACC, especially in patients at high risk
for antimicrobial resistance such as healthcare-associated
infections. It has been reported that positive rates of either
bile or gallbladder cultures range from 29 to 54 % for acute
cholecystitis [51–58]. In Table 3 are reported the anti-
microbial regimens suggested for ACC.
Patient selection for surgery: risk stratification (i.e.
definition of high risk patients)
ACC is a heterogeneous condition. The severity of in-
flammation and its life-threatening potential is strongly
determined by the general status of the patient. It could
be argued that alternative treatment to early cholecystec-
tomy could be of benefit for patients with reduced func-
tional reserve. Our search reviewed the available literature
to identify the parameters to stratify the risk of surgery in
this population and verify if there is any available method
to select the best course of action in selected high-risk
groups.
Statement 4.1 Patient’s age above 80 in ACC is a risk factor
for worse clinical behaviour, morbidity and mortality.
(LoE 3 GoR B)
Several studies identify old age as a perioperative risk
factor for cholecystectomy. However, it is not clear if
early laparoscopic cholecystectomy is the best treatment
Table 2 Antibiotics commonly used to treat biliary tract
infections and their biliary penetration ability [46]
Good penetration efficiency
(ABSCR > =1)
Low penetration efficiency
(ABSCR <1)
Piperacillin/tazobactam (4.8) Ceftriaxone (0.75)
Tigecycline (> 10) Cefotaxime (0.23)
Amoxicillin/clavulanate (1.1) Meropenem (0.38)
Ciprofloxacin (> 5) Ceftazidime (0.18)
Ampicillin/Sulbactam (2.4) Vancomycin (0.41)
Cefepime (2.04) Amikacin (0.54)
Levofloxacin (1.6) Gentamicin (0.30)
Penicillin “G” (>5)
Imipenem (1.01)
ABSCR Antibiotics Bile/Serum Concentration Ratio
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option for elderly patients with ACC. In the retrospect-
ive cohort study by Kirshtein et al, the age groups above
and below 75 showed a significant difference in mortal-
ity (4.8 % versus 0.5 %), morbidity (31 % versus 15 %),
and average hospital stay (3.9 versus 2.8) [59]. A recent
study by Nielsen et al reported that the odds ratio for
mortality in ACC patients older than 80 years with low
anaesthetic risk (American Score of Anaesthesiologist I-
II (ASA) was significantly higher than in the age groups
of 65 to 79 and 50 to 64 (30.9 % vs 5.5 % vs 1 %) [60].
According to Girgin et al, patients’ age, Mannheim peri-
tonitis index ≥29, and co-morbidities are significantly re-
lated to morbidity, while increased age and low WBC
count are significantly related to mortality in gangrenous
cholecystitis [61]. In the case series by Lupinacci et al,
mortality of patients older than 80 years was 34.2 % in
urgent cholecystectomy versus 0 % in both the elective and
semi-elective groups. Statistically significant differences
were also demonstrated in morbidity and length of hospital
stay. However, the study showed a significantly higher inci-
dence of patients with ASA score of III and IV in the ur-
gent cholecystectomy group (76 % versus 25.6 % versus
28.6 %), and a notably lower number (20 % versus 81.3 %
versus 82.8 %) of laparoscopic cholecystectomies [62].
Few retrospective cohort studies compare the outcome
of early versus delayed cholecystectomy in aged ACC pa-
tients. They fail to demonstrate a significant difference
in mortality and postoperative complications [63–66]. A
study by Cull et al showed that recurrent episodes of
pancreatitis, cholecystitis, and cholangitis were signifi-
cantly less likely after early than delayed cholecystectomy,
irrespective of whether delayed cholecystectomy was
preceded by percutaneous cholecystostomy [65]. These
findings confirmed the results of a recent population-
based analysis on a sample of the Medicare Claims Data
System. In this analysis, a lack of a definitive surgical treat-
ment at the index admission in an aged population is asso-
ciated with 38 % gallstone-related readmission rate in two
years versus 4.4 % in similar patients who had early chole-
cystectomy [67].
Statement 4.2 The co-existence of diabetes mellitus
does not contraindicate urgent surgery but must be
re-considered as a part of the overall patient comorbidity
(LoE 3 GoR C)
In 1995, Shpitz et al showed a greater incidence of car-
diovascular disease and associated bacterobilia in dia-
betics who underwent urgent cholecystectomy for ACC;
however, they did not report a significant difference in
the postoperative outcome [68]. A recent analysis of a
large ACC cholecystectomy series from the American
College of Surgeons National Surgical Quality Improve-
ment Program database demonstrated that diabetes in-
creased the risk of mortality (4.4 % versus 1.4 %, adjusted
odds ratio (OR) 1.79 (95 % CI: 1.09 to 2.94), adjusted P
value = 0.022), cardiovascular events (2.3 versus 0.5 %; OR
2.50 (95 % CI: 1.25 to 4.99); adjusted P value = 0.010), and
renal failure (2.5 versus 0.3 %; OR 3.91 (95 % CI: 1.82 to
8.40); adjusted P value = 0.001) [69]. A second study on the
same series showed that delay in surgery in diabetic pa-
tients was associated with significantly higher odds of de-
veloping surgical site infections and a longer hospital stay.
The same findings were not found in the non-diabetic
Table 3 Antimicrobial regimens suggested for acute calculous cholecystitis
Community acquired Health-care associated
1) Beta-lactam/beta-lactamase inhibitor combinations based regimens
AMOXICILLIN/CLAVULANATE (in stable patients)
TICARCILLIN/CLAVULANATE (in stable patients)
PIPERACILLIN/TAZOBACTAM (in unstable patients)
2) Cephalosporins based regimens
CEFTRIAZONE + METRANIDAZOLE (in stable patients)
CEFEPIME +METRANIDAZOLE (in stable patients)
CEFTAZIDIME +METRANIDAZOLE (in stable patients)
CEFOZOPRAM +METRANIDAZOLE (in stable patients)
3) Carbapenem based regimens
ERTAPENEM (in stable patients)
IMIPENEM/CILASTATIN (only in unstable patients)
MEROPENEM (only in unstable patients)
DORIPENEM (only in unstable patients)
4) Fluoroquinolone based regimens (In case of allergy to beta-lactams)
CIPROFLOXACIN +METRONIDAZOLE (only in stable patients)
LEVOFLOXACIN +METRONIDAZOLE (only in stable patients)
MOXIFLOXACIN (only in stable patients)
5) Glycylcycline based regimen
TIGECYCLINE (in stable patients if risk factors for ESBLs)
TIGECYCLINE + PIPERACILLIN/TAZOBACTAM (in stable patients)
IMIPENEM/CILASTATIN +/- TEICOPLANIN (only in unstable patients)
MEROPENEM +/- TEICOPLANIN (only in unstable patients)
DORIPENEM +/- TEICOPLANIN (only in unstable patients)
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patients of the same series [70], suggesting that a prompt
course of action is appropriate in diabetics.
Statement 4.3 Currently, there is no evidence of any scores
in identifying patient’s risk in surgery for ACC. ASA,
POSSUM and APACHE II are correlated to surgical risk in
patients with gallbladder perforation, higher accuracy
being for APACHE II. However, APACHE II is built to predict
morbidity and mortality in the patients admitted to ICU: its
use as a preoperative score should be considered as an
extension usage from the original concept. (LoE 4 GoR C).
Therefore, prospective and multicentre studies to compare
different risk factors and scores are necessary
None of the available clinical scores for the evaluation of
surgical risk for acute conditions has been validated for
ACC. Recently, the Tokyo guidelines attempted to ad-
dress the heterogeneity of the ACC population with a
therapeutic algorithm that includes some elements of
risk stratification. They suggest a staging system based
upon severity assessment criteria such as degree of local
inflammation and patient conditions, without including
any of the most commonly adopted risk stratification
scores [71]. However, their classification lacks a clinical
validation and has not been validated by studies showing
an improved outcome after its introduction. In fact, a
retrospective series failed to find any significant benefit
[13]. In 2006, Yi et al stratified the risk in relation to the
ASA score. The study shows a significant difference in
morbidity (20 % versus 9.1 %) in patients in ASA III vs
ASA I, with no significant difference in the conversion
rate, recovery time or hospital postoperative stay [72]
The only available comparison of risk assessment scores
(ASA, APACHE II and POSSUM) is limited to series of
perforated ACC. The study highlights a significant asso-
ciation of the three scores with morbidity and mortality.
Both POSSUM and APACHE II were superior to ASA in
risk prediction [73]. Finally, we would like to point out
that the usefulness of any score is to add but not to
trump surgical judgement: in other words not all patient
variables (e.g. recent coronary stent or recent pulmonary
embolism, etc.) will be included in any score.
Timing for surgery: what is early cholecystectomy?
Several randomised controlled trials have investigated
early laparoscopic cholecystectomy versus delayed lap-
aroscopic cholecystectomy [74–82].
Early and delayed laparoscopic cholecystectomy have
been defined differently in different trials. In general, early
laparoscopic cholecystectomy has been defined variably as
that performed in patients with acute cholecystitis with
symptoms less than 72 h or symptoms less than 7 days
but within 4 to 6 days of diagnosis. This roughly translates
to 10 days from onset of symptoms. The delayed lap-
aroscopic cholecystectomy is defined variably as that
performed between 7 days to 45 days and that per-
formed at least 6 weeks after initial diagnosis.
Statement 5.1 Early laparoscopic cholecystectomy is
preferable to delayed laparoscopic cholecystectomy in
patients with ACC as long as it is completed within 10 days
of onset of symptoms (LoE 1 GoR A)
Different patients were included in the trial and the defi-
nitions of early laparoscopic cholecystectomy used by
these trials comparing early laparoscopic cholecystectomy
versus delayed laparoscopic cholecystectomy performed
within 6 weeks after initial diagnosis were different in vari-
ous studies. Six trials provided clinical results. Overall, the
systematic review and meta-analysis of randomised con-
trolled trials which included clinical data from five of these
six trials demonstrated no significant difference in the
complication rate or conversion to open cholecystectomy
between early and delayed laparoscopic cholecystectomy
and a hospital stay which was statistically shorter by
4 days in the early laparoscopic cholecystectomy group
compared to the delayed laparoscopic cholecystectomy
group [37]. One trial which was not included in the
systematic review also showed similar results as the
systematic review (i.e. there was no significant differ-
ence in the complication rate between early and de-
layed laparoscopic cholecystectomy and the hospital
stay was shorter by 4 days in the early laparoscopic
cholecystectomy group compared to the delayed lap-
aroscopic cholecystectomy group) despite including
participants with symptoms > 72 h [81].
Statement 5.2 Laparoscopic cholecystectomy should not be
offered for patients beyond 10 days from the onset of
symptoms unless symptoms suggestive of worsening
peritonitis or sepsis warrant an emergency surgical
intervention. In people with more than 10 days of
symptoms, delaying cholecystectomy for 45 days is better
than immediate surgery (LoE 2 GoR B)
One trial compared early laparoscopic cholecystectomy
versus delayed laparoscopic cholecystectomy performed
between 7 days and 45 days after initial diagnosis [83].
In this trial, the duration of symptoms in the partici-
pants was not reported. early laparoscopic cholecystec-
tomy was performed within 24 h of admission while
delayed laparoscopic cholecystectomy was performed
between 7 days and 45 days. This trial demonstrated that
the morbidity was higher in the delayed laparoscopic
cholecystectomy compared to early laparoscopic chole-
cystectomy group and the length of hospital stay was
5 days longer in the delayed laparoscopic cholecystec-
tomy group compared to early laparoscopic cholecystec-
tomy group [83]. There was no significant difference in
the conversion to open cholecystectomy between the
two groups [83].
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Statement 5.3 Early laparoscopic cholecystectomy should
be performed as soon as possible but can be performed up
to 10 days of onset of symptoms. (Level 1 Evidence; Grade
A recommendation). However, it should be noted that
earlier surgery is associated with shorter hospital stay and
fewer complications (LoE 2 GoR B)
One randomised controlled trial compared early lap-
aroscopic cholecystectomy as soon as surgical schedule
allows with early laparoscopic cholecystectomy after
resolution of symptoms but within 5 days of admission
[74] in patients with ACC. The duration of symptoms
prior to admission was not reported in this trial. There
was no statistically difference in the complication rate
or conversion to open cholecystectomy between pa-
tients who underwent surgery as soon as the schedul-
ing allowed compared to those who underwent surgery
after resolution of symptoms but within 5 days of ad-
mission [74]. However, the length of hospital stay was
shorter in patients who underwent surgery as soon as
the scheduling allowed compared to those who under-
went surgery after resolution of symptoms but within
5 days of admission [74]. Evidence from a large data-
base review including approximately 95,000 patients
with ACC demonstrated that patients who had surgery
within 2 days of admission had fewer complications than
those who underwent surgery between 2 and 5 days of ad-
mission, and those who had surgery between 6 days and
10 days of presentation. There was no significant differ-
ence in the groups between conversion to open surgery
[84]. Finally, several studies suggest that cholecystectomy
performed as soon as possible, especially in the sce-
nario of an Acute Care Surgery Service, is cost-effective
[83, 85, 86].
Type of surgery
Statement 6.1 In ACC, a laparoscopic approach should
initially be attempted except in case of absolute
anaesthesiology contraindications or septic shock
(LoE 2 GoR B)
According to Tokyo Guidelines 2013 (TG13), laparoscopic
cholecystectomy is now accepted as a safe surgical tech-
nique when it is performed by expert surgeons even in the
setting of ACC. TG13 described the surgical treatment of
ACC according to the degree of severity of the disease.
early laparoscopic cholecystectomy is indicated for pa-
tients with Grade I (Mild) ACC. early laparoscopic chole-
cystectomy is indicated also for patients with Grade II
(Moderate) ACC in experienced centers, but in the case of
severe signs of local inflammation (WBC > 18.000; a palp-
able tender mass in the right upper quadrant and >72 h
from the onset) should be indicated a conservative treat-
ment with gallbladder drainage followed by a delayed chole-
cystectomy. For patients with severe local complications
such as biliary peritonitis, emphysematous cholecystitis,
gangrenous cholecystitis and purulent cholecystitis, emer-
gency surgery is conducted (open or laparoscopic) along
with the usual supportive measures. For Grade III (Severe)
ACC, TG13 suggest gallbladder drainage and delayed
cholecystectomy after improvement of general clinical
conditions [71]. Some Scientific Societies also support,
more strongly than TG13, laparoscopic cholecystec-
tomy in ACC as the first line approach [87–89].
Statement 6.2 Laparoscopic cholecystectomy for ACC is
safe, feasible, with a low complication rate and associated
with shortened hospital stay (LoE 1 GoR A)
Although Borzellino et al. in their meta-analysis suggested
that laparoscopy is not indicated for all cases of ACC due
to the difficulty of cholecystectomy in patients with severe
inflammation [90], several recent case control, randomized
clinical trials have compared laparoscopic cholecystectomy
to open cholecystectomy in ACC [91–100]. A recently
published meta-analysis demonstrated that laparoscopic
cholecystectomy in ACC is the preferable approach with
lower mortality and morbidity, significantly shorter post-
operative hospital stay and reduced rate of pneumonia
and wound infections, compared to the open technique.
Conversion rate ranged from 8 to 35 % [101].
Statement 6.3 Among high-risk patients, in those with Child
A and B cirrhosis, advanced age >80, or pregnant women,
laparoscopic cholecystectomy for ACC is feasible and safe
(LoE 3 GoR C)
Some studies suggested that laparoscopic cholecystectomy
should be the first line approach in specific categories of pa-
tients such as the elderly or pregnant women [102, 103].
According to meta-analysis published by de Goede et al.,
elective laparoscopic cholecystectomy in patients with
Child A or B cirrhosis is associated with significantly
less postoperative complications, shorter duration of
hospitalization and shorter time to resume normal diet
compared to open technique [104]. According to Lucidi
et al. laparoscopic cholecystectomy should be recom-
mended as the first choice approach in cirrhotic patients;
however recommendation for laparoscopic cholecystec-
tomy in patients with Child C cirrhosis is not clear [105].
Cirrhosis is a major risk factor for surgery. laparoscopic
cholecystectomy in cirrhotic patients is associated with
significantly prolonged duration of surgery, increased
operative blood loss, conversion rate, hospital stay and
overall morbidity and mortality when compared with non-
cirrhotic patients [106]. Laparoscopic cholecystectomy-
related morbidity in cirrhotic patients is directly related to
the Child Pugh score [107, 108]. In patients with advanced
cirrhosis and severe portal hypertension, specific technical
difficulties may be encountered, due to the presence of a
portal cavernoma, the difficulty in exposure of Calot’s tri-
angle and dissection of the gallbladder hilum, the presence
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of adhesions and neovascularization or the difficulty in
controlling bleeding from the liver bed. Subtotal chole-
cystectomy can avoid many of these difficulties [109].
In conclusion, laparoscopic approach should be the first
choice for the cholecystectomy in Child A and B pa-
tients. The approach to patients with Child Pugh C no-
compensated cirrhosis remains a matter of debate. As a
first recommendation, cholecystectomy should be avoi-
ded in these patients, unless clearly indicated, such as
in ACC not responding to antibiotics [105].
Statement 6.4 Laparoscopic or open subtotal
cholecystectomy is a valid option for advanced
inflammation, gangrenous gallbladder, or any setting of
the “difficult gallbladder” where anatomy is difficult to
recognize and main bile duct injuries are more likely (LoE 2
GoR A)
A recent systematic review with meta-analysis by Elshaer
et al. reported that subtotal cholecystectomy was per-
formed using the laparoscopic (72.9 %), open (19.0 %)
and laparoscopic converted to open (8.0 %) techniques.
The most common indications were severe cholecystitis
(72.1 %), followed by cholelithiasis in liver cirrhosis and
portal hypertension (18.2 %) and empyema or perforated
gallbladder (6.1 %). They concluded that subtotal chole-
cystectomy is an important tool in the difficult chole-
cystectomy and achieves morbidity rates comparable to
those reported for total cholecystectomy in simple cases
[110]. Alternative surgical strategy is the fundus first ap-
proach to reach progressively the infundibulum, cystic
duct and artery: also by using this thecnique the risk of
lesions must be always kept in mind [111, 112].
Statement 6.5 In case of local severe inflammation,
adhesions, bleeding in Calot’s triangle or suspected bile
duct injury, conversion to open surgery should be strongly
considered. (LoE 3 GoR B)
Tang et al. in their systematic review, identified the princi-
pal risk factors for conversion during laparoscopic chole-
cystectomy. Single factors that appear to be important
include male gender, extreme old age, morbid obesity, cir-
rhosis, previous upper abdominal surgery, severe acute and
chronic cholecystitis, and emergency laparoscopic chole-
cystectomy. The combination of patient and disease related
risk factors increases the conversion rate [113]. According
to Giger et al., extensive inflammation, adhesions and con-
sequent increased oozing can make laparoscopic dissection
of Calot’s triangle and recognition of the biliary anatomy
hazardous and difficult. Therefore, conversion to open sur-
gery is strongly recommended to secure patient safety in
such difficult conditions [114]. An elevated WBC count
(>18 × 10(9)/L) and fever > 38 °C are predictive for the de-
velopment of complications and conversion [115]. Sugrue
et al. recently published the proposal of a new scoring
system to evaluate the intraoperative difficulty of the chole-
cystectomy in order to provide objective suggestion for
conversion to open technique [116] and results may clarify
and standardize the definition of “difficult surgery”. Ac-
cording to Eldar et al. the complication rate in ACC tended
to be associated with duration of complaints >48 h,
gangrenous cholecystitis, male sex, age >60 years, other
associated diseases, larger bile stones and elevated serum
bilirubin levels. Generally, laparoscopic cholecystectomy is
safe in all forms of ACC, with acceptably low conversion
and complication rates, [117] excluding gangrenous chole-
cystitis where a conversion rate range between 4 to 40 %
[87, 117]. In conclusion gangrenous gallbladder, obscure
anatomy, bleeding, bile duct injuries, adhesions and previ-
ous upper abdominal surgery represent clinical conditions
for which conversion to open cholecystectomy should be
strongly considered [118].
Associated common bile duct stone: suspicion and
diagnosis at the presentation
Choledocholithiasis, i.e. the presence of common bile
duct stones (CBDS), is reported ro occur in10% to 20 %
in case series of cholelithiasis, with lower incidence during
ACC ranging from 5 to 15 % of the patients [119–122].
Investigation for CBDS require time and can delay the
surgical intervention. Due to the relatively low incidence
of CBDS during ACC, the issue is to select patients with a
high likelihood of CBDS who would benefit from further
diagnostic tests and eventually the removal of the stones.
An uncommon condition that mimics CBDS is the Mirizzi
syndrome which occurs in 1 % of patients with chole-
lithiasis: preoperative investigation may help in the
diagnosis although the vast majority are identified at
surgery [123, 124].
Statement 7.1 Elevation of liver biochemical enzymes and/
or bilirubin levels are not sufficient to identify ACC patients
with choledocholithiasis and further diagnostic tests are
needed. (LoE 2 GoR B)
Liver biochemical tests historically have a great utility in
determining the presence of CBDS. However, the majority
of published studies are not in patients with ACC and also
include asymptomatic cholelithiasis. Normal liver bioche-
mical tests have a negative predictive value of 97 %,
whereas the positive predictive value of any abnormal liver
biochemical test result is only 15 % [125]. Positive predict-
ive value of liver function studies is a poor tool for predic-
tion of CBDS, even in non-ACC, with results ranging
from 25 to 50 % [119, 126, 127]. In fact, in ACC, liver bio-
chemical tests may be altered due to the acute inflamma-
tory process of the gallbladder and the biliary tree. 15 to
50 % of patients with ACC show elevation in liver en-
zymes without choledocholithiasis. Song et al demon-
strated that 424 of 1178 patients with ACC had increased
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liver tests (alanine transaminase (ALT), aspartate trans-
aminase (AST) greater than twice normal levels). Of these
only 246 (58 %) had choledocholithiasis [128]. Chang et al
showed that 51 and 41 % of ACC patients without choled-
ocholithiasis had elevated ALT and AST, respectively.
However, increased bilirubin levels with leukocytosis may
predict gangrenous cholecystitis [129]. Padda et al demon-
strated that approximately 30 % of patients with ACC
without choledocholithiasis had abnormal alkaline phos-
phatase (ALP) and/or bilirubin and 50 % had abnormal
ALT. Among patients with ACC and choledocholithiasis,
77 % had abnormal ALP, 60 % abnormal bilirubin and
90 % elevated ALT. By multivariate analysis increased
common bile duct size and elevated ALT and ALP were
predictors of choledocholithiasis [130]. The diagnostic ac-
curacy increases for cholestasis tests such serum bilirubin
with the duration and the severity of obstruction. Specifi-
city of serum bilirubin level for CBDS was 60 % with a
cut-off level of 1.7 mg/dL and 75 % with a cut-off level of
4 mg/dL [126]; however, mean level of bilirubin in patients
with CBDS is generally lower (1.5 to 1.9 mg/dL) [119, 127].
In a prospective study, Silvestein reported the diagnostic
accuracy of serum bilirubin and serum ALP at two cut-offs
for each test. Serum bilirubin at a cut-off of greater than
22.23 μmol/L had a sensitivity of 0.84 (95 % CI 0.65 to
0.94) and a specificity of 0.91 (0.86 to 0.94). Bilirubin at a
cut-off of greater than twice the normal limit, had a sensi-
tivity of 0.42 (95 % CI 0.22 to 0.63) and a specificity of 0.97
(95 % CI 0.95 to 0.99). For ALP at a cut-off of greater than
125 IU/L, sensitivity was 0. 92 (95 % CI 0.74 to 0.99) and
specificity was 0.79 (95 % CI 0.74 to 0.84). For ALP at a
cut-off of greater than twice the normal limit, sensitivity
was 0.38 (95 % CI 0.19 to 0.59) and specificity was 0.97
(95 % CI 0.95 to 0.99) [131, 132].
Statement 7.2 At AUS, the visualization of CBDS is a very
strong predictor of choledocholithiasis. (LoE 5 GoR D).
Indirect signs of stone presence such as increased diameter
of common bile duct are not sufficient to identify ACC
patients with choledocholithiasis and further diagnostic
tests are needed. (LoE 1 GoR A)
AUS is the preferred imaging technique to diagnose
ACC. Simultaneously, the common bile duct can be visual-
ized and investigated. A recently published meta-analysis
investigated the diagnostic potential of ultrasound [131]:
sensitivity ranged from 0.32 to 1.00 with a summary sensi-
tivity of 0.73 (95 % CI 0.44 to 0.90), and specificity ranged
from 0.77 to 0.97 with a summary specificity of 0.91 (95 %
CI 0.84 to 0.95). In a retrospective analysis, Boys et al [133]
demonstrated that AUS mean common bile duct diameter
in ACC patients without and with CBDS was 5.8 and
7.1 mm, respectively (P value = 0.004). Diameter >10 mm
was associated with 39 % incidence of CBDS, while
diameter < 9.9 mm was associated with common bile
duct stones in 14 %. The authors’ conclusion was that
AUS common bile duct diameter is not sufficient to
identify patients at significant risk for CBDS.
Statement 7.3 Liver biochemical tests, including ALT, AST
bilirubin, ALP, gamma glutamyl transferase (GGT), AUS
should be performed in all patients with ACC to assess the
risk for CBS. (LoE 2 GoR B)
Several predictive scores of CBDS have been proposed
and validated but none are specific for ACC. The imple-
mentation of these predictive scores in clinical practice is
poor [126, 134–138]. All combine the same clinical vari-
ables differently. Hugrier et al combined diameter of com-
mon bile duct > 12 mm, gallstones < 10 mm, advanced age
and symptomatic disease; Barkun et al combined age > 55,
elevated serum bilirubin, dilated common bile duct and
evidence of CBDS; Menezes combined age > 55, male sex,
ascending cholangitis, dilated common bile duct, CBDS,
and abnormal liver tests; Soltan et al included history of
symptomatic disease, abnormal liver tests, dilated com-
mon bile duct and presence of CBDS; Sun et al included
male sex, abnormal liver test and dilated common bile
duct; Sarli et al combined positive AUS and abnormal liver
tests. The American Society of Gastrointestinal Endoscopy
and the Society of American of Gastrointestinal Endo-
scopic Surgeons combined the various published validated
clinical scores and proposed a risk stratification of CBDS
in three different classes: low risk (<10 %), moderate (10
to 50 %) and high risk (> 50 %), based on the presence of
predictive factors for having CBDS in its guidelines [139].
This proposed classification has clear clinical implications.
Patients with a low risk of CBDS should be operated upon
without further investigation. Patients with moderate risk
should be interrogated with a second level examination:
preoperatively by endoscopic ultrasound (EUS) or mag-
netic resonance cholangiopancreatography (MRCP) or in-
traoperatively by laparoscopic ultrasound or laparoscopic
cholangiography, to select patients who need stone re-
moval prior, during or after surgery. Patients with high
risk of CBDS should undergo directly preoperative diag-
nostic and therapeutic ERCP.
Statement 7.4 common bile duct stone risk should be
stratified according to the proposed classification, modified
from the American Society of Gastrointestinal Endoscopy
and the Society of American Gastrointestinal Endoscopic
Surgeon Guidelines (LoE 5 GoR D)
ASGE guidelines seem to be the best tool available for the
diagnosis and the management of CBDS during ACC
[139]. However, according to this classification high risk
patients have a probability of having CBDS > 50 %: this
means that up to 49 % of patients that undergo ERCP may
have no CBDS and, given the potential complications of
ERCP, this is not acceptable. For this reason we prefer a
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more cautious approach: only patients with evidence of
CBDS at AUS should be considered at high risk of CBDS
and should undergo directly diagnostic and therapeutic
ERCP; patients with total serum bilirubin > 4 mg/dL, or
enlarged common bile duct diameter at AUS plus biliru-
bin level 1.8 to 4 mg/dL should be considered as moderate
risk and should undergo second level investigation such as
EUS/MRCP, or intraoperative Laparoscopic ultrasound/
cholangiography to avoid the ERCP complications. See
Table 4 for the modified risk stratification.
Statement 7.5 Patients with moderate risk for
choledocholithiasis should undergo preoperative MRCP,
EUS, intraoperative cholangiography, or Laparoscopic
ultrasound depending on the local expertise and
availability. (LoE 1 GoR A)
Two preoperative imaging techniques are available for
the detection of CBDS, MRCP and EUS. These diag-
nostic tools, according to the ASGE guidelines [139]
should be reserved for patients with moderate risk for
choledocholithiasis and have been shown to delay de-
finitive ACC treatment [133]. On the other hand, these
tests could exclude the presence of CBDS with high
diagnostic accuracy, thereby avoiding further invasive
procedures such ERCP or intraoperative cholangiog-
raphy and their complications. In fact, the implemen-
tation of these techniques resulted in a reduction of
ERCP ranging from 30 to 75 % in non-selected pa-
tients. [140–142]. A Cochrane meta-analysis compared
these two different techniques [143]: both had good
diagnostic accuracy and did not differ significantly
with a summary sensitivity of 95 % for EUS and 93 %
for MRCP and a summary specificity of 97 and 96 %
respectively. As noted by some authors interpreting
similar results, considerations other than diagnostic effi-
cacy (local availability, costs, expertise, delay of surgery)
might be important when deciding which imaging method
to use [144].
Statement 7.6 Patients with high risk for choledocholithiasis
should undergo preoperative ERCP, intraoperative
cholangiography, Laparoscopic ultrasound, depending on
the local expertise and the availability of the technique.
(LoE 1 GoR A)
ERCP has both a diagnostic and therapeutic role in the
management of choledocholithiasis but is an invasive pro-
cedure with potential severe complications. The literature
emphasizes that diagnostic ERCP has risks. Morbidity as-
sociated with diagnostic ERCP includes pancreatitis, chol-
angitis, haemorrhage, duodenal perforation, or allergy to
contrast. These occur in 1 to 2 % and increase to 10 %
when associated with sphincterotomy [145–148]. On the
other hand intraoperative cholangiography significantly
increases the length of surgery [149] and requires dedi-
cated staff in the operating room. This is not always avail-
able, especially in the acute setting with non-planned
operation as in ACC. Positive findings on intraoperative
cholangiography lead to intraoperative management of
CBDS with additional operative time. A recently published
meta-analysis compared the two techniques [131]: for
ERCP, the summary sensitivity was 0.83 (95 % confidence
interval 0.72 to 0.90) and specificity was 0.99 (95 % CI
0.94 to 1.00). For intraoperative cholangiography, the
summary sensitivity was 0.99 (95 % CI 0.83 to 1.00) and
specificity was 0.99 (95 % CI 0.95 to 1.00). Sensitivities
showed a weak statistical difference (p = 0.05) but due to
the quality and the methodology of the included stud-
ies, the two diagnostic techniques should be consid-
ered equivalent. Recently, Laparoscopic ultrasound has
been introduced for the detection of CBDS. A recent
meta-analysis has shown that intraoperative cholangi-
ography and Laparoscopic ultrasound have the same
pooled sensitivity and similar pooled specificity for the
detection of CBDS [150]. As in the case of intraopera-
tive cholangiography, intraoperative evidence of CBDS
leads to intraoperative management of common bile
duct with additional operating time.
Statement 7.7 CBDS could be removed preoperatively,
intraoperatively, or postoperatively according to the local
expertise and the availability of the technique.
(LoE 1 GoR A)
CBDS could be removed with varying techniques in
different timings: preoperative ERCP with sphincterot-
omy, intraoperative ERCP with sphincterotomy, lap-
aroscopic or open common bile duct exploration, or
post-operative ERCP with sphincterotomy. A system-
atic review assessed the difference between these
Table 4 Predictive factors and risk classes for choledocholithiasis
Predictive factor for choledocholithiasis
Very strong Evidence of common bile duct stone at abdominal
ultrasound
Strong Common Bile duct diameter > 6 mm (with gallbladder
in situ)
Total Serum Bilirubin > 4 mg/dL
Bilirubin level 1.8 to 4 mg/dL
Moderate Abnormal liver biochemical test other than bilirubin
Age older than 55 years
Clinical gallstone pancreatitis
Risk class for choledocholithiasis
High Presence of any VERY STRONG
Low No predictors present
Intermediate All other patients
Modified from [139]
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different techniques [151]. No differences in terms of
morbidity, mortality and success rate were reported
comparing these methods. Therefore, these techniques
should be considered suitable options. Another meta-
analysis investigated two different techniques for ERCP
plus sphincterotomy: preoperative or intraoperative with
the rendezvous technique [152]. These two techniques
were equal in safety and efficacy; intraoperative technique
reduced the risk for post-ERCP pancreatitis, but obviously
requires dedicated staff in the theatre and prolongs the
length of surgery.
Alternative treatments for high risk patients
Statement 8.1 Gallbladder drainage, together with
antibiotics, converts a septic cholecystitis into a non-septic
condition; however the level of evidence is poor
(LoE 4, GoR C)
As already stated, the definitive treatment of ACC is
early laparoscopic cholecystectomy. However some pa-
tients may not be suitable candidates for surgery, due to
co-morbidities. Cholecystectomy for ACC in the elderly
and in high risk patients has always been considered a
high-risk procedure with a reported morality up to 19 %
[153]. Recently published articles show that emergency
cholecystectomy for ACC could be considered a feasible
and safe procedure [89, 153–157].
Gallbladder drainage, also known as percutaneous
cholecystostomy (PC) is a potential alternative to cho-
lecystectomy in high-risk patients, but its role is diffi-
cult to determine because different definitions are used
to identify “high-risk” patients. Gallbladder drainage
decompresses the infected bile or pus in the gallblad-
der, removing the infected collection without removing
the gallbladder. The removal of the infected material,
in addition to antimicrobial therapy, can result in a re-
duced inflammation with an improvement of the clin-
ical condition. Several case series, retrospective and
observational studies exist on cholecystostomy. A sys-
tematic review of the literature included 53 studies
with 1918 patients outlining a high success rate of the
procedure (85.6 %) with a low procedure related mor-
tality (0.36 %); however, the 30-day mortality was
15.4 % [153]. A major limitation of the study was the
inclusion of patients with both acute acalcolus chole-
cystitis and ACC. After the aforementioned review,
about 27 further observational studies have been pub-
lished, confirming that the groups considered in the
studies, their inclusion criteria, the results and even
the conclusions reached by different authors are
largely non-homogeneous [158]. With these limitations
in mind, the reported in-hospital mortality for chole-
cystostomy varies between 4 and 50 % and morbidity
ranges between 8.2 and 62 %.
Statement 8.2 Among standardized gallbladder drainage
techniques percutaneous transhepatic gallbladder drainage
(PTGBD) is generally recognized as the preferred technique
due to the ease and the reduced costs. (LoE 4, GoR C)
Cholecystostomy can be performed with several differ-
ent techniques as summarized well by the TG [159].
These include PTGBD, percutaneous transhepatic gall-
bladder aspiration (PTGBA), endoscopic naso-biliary
gallbladder drainage, endoscopic gallbladder stenting,
and EUS-guided gallbladder drainage via the antrum of
the stomach and the duodenum. A controlled trial by
Ito et al. [160] compared PTGBD with PTGBA. All pa-
tients with ACC were treated conservatively and patients
who showed no improvements after 24 h were random-
ized to receive either PTGBD or PTGDA. PTGBD was
superior to gallbladder aspiration in terms of clinical ef-
fectiveness with the same complication rate as gallblad-
der aspiration. However this trial included high risk
and low risk patients. No other good quality evidence
exists on which is the best gallbladder drainage technique.
Finally, in case of evidence of cystic duct obstruction,
PTGDB should be, even more, the preferred technique for
gallbladder drainage.
Statement 8.3 PC could be considered as a possible
alternative to surgery after the failure of conservative
treatment in a small subset of patients unfit for emergency
surgery due to their severe co-morbidities (LoE 2 GoR B)
TG on ACC [11] consider the gallbladder drainage as
mandatory in the severe grade (according to the Tokyo
classification [12]) acute cholecystitis and also suggest its
use in the moderate grade if conservative treatment fails.
The panel of the Tokyo Guidelines states that it is known
to be an effective option in critically ill patients, especially
in elderly patients and patients with complications; how-
ever, there is a lack of good quality evidence to support
the statement. Hatzidakis et al. published in 2002 a ran-
domized trial comparing PC with conservative treatment
in patients with acute acalcolus cholecystitis or ACC
[161]: there were no significant differences in mortality
and morbidity. Akyurek et al published in 2005 a trial
where patients with ACC were randomized to receive PC
followed by early laparoscopic cholecystectomy or conser-
vative treatment followed by delayed laparoscopic chole-
cystectomy [162]. There were no differences in term of
mortality and morbidity; PC plus early laparoscopic chole-
cystectomy resulted in a reduction of the length of stay
and of costs. Melloul et al. in 2011 published a retrospect-
ive case control study in critically ill patients with biliary
sepsis treated by early laparoscopic cholecystectomy or
PC [163]: mortality was not different between the two
treatments but early laparoscopic cholecystectomy was as-
sociated with significantly higher complication rate. A
Spanish retrospective study [164] compared critically ill
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patients with ACC who underwent PC or early laparo-
scopic cholecystectomy. They found a significantly higher
mortality rate in the PC group; however this study is of
poor quality and has several limitations such as the retro-
spective study design and the selection bias. A Cochrane
systematic review by Gurusamy et al. investigated the role
of cholecystostomy: authors included the only two random-
ized trials, both at high risk of bias, concluding that “we are
unable to determine the role of percutaneous cholecystost-
omy in the clinical management of high-risk surgical pa-
tients with acute cholecystitis” [165]. Currently, the
CHOCOLATE trial is ongoing [161]: it is a randomized
controlled trial comparing PC with early laparoscopic
cholecystectomy in critically ill patients (APACHE score 7–
14) with ACC; results may clarify the real role of the percu-
taneous drainage. Gallbladder drainage has been even de-
scribed as a procedure reserved for those patients who
failed the conservative treatment after a variable time of 24
to 48 h. A prospective study by Barak et al. [166] reported
age above 70 years, diabetes, tachycardia, and a distended
gallbladder at admission as predictors for the failure of con-
servative treatment at 24 h follow-up, while WBC > 15,000
cell/mm3, elevated temperature, and age above 70 years
were predictors for the failure of conservative treatment at
48 h follow-up. There is no specific antibiotic regimen to
be prescribed alongside PC. None of the examined studies
reported the specific drug agent. No evidence exists sup-
porting the need for a peculiar antibiotic regimen. For the
antimicrobial therapy, please see the dedicated section. At
the present time, PC seems to be a safe and effective pro-
cedure in critically ill patients with ACC. However, no evi-
dence supports its superiority toward the conservative
treatment or early laparoscopic cholecystectomy.
Statement 8.4 delayed laparoscopic cholecystectomy could
be offered to patients after reduction of operative and
anesthesiology- related risks to reduce further
hospitalization (LoE 5 GoR D)
De Mestral et al. published a large retrospective epi-
demiological analysis in 2012 showing that only 40 % of
patient underwent delayed laparoscopic cholecystectomy
after PC; the 1 year readmission rate for patients who
did not undergo delayed laparoscopic cholecystectomy
after PC was 49 % with an in-hospital mortality of 1 %
[10]. No randomized trial comparing the need for de-
layed laparoscopic cholecystectomy exists currently.
Conclusion: grey areas and opportunities for
future research
After achieving the consensus for all the statements, the
participants to the Consensus Conference voted for the
WSES algorithm on ACC which is reported in Fig. 1.
Based on the evidence included in the present guidelines,
it can be stated that early laparoscopic cholecystectomy is
the best therapeutic approach for ACC and that post-
operative antibiotics are not necessary in cases of uncom-
plicated cholecystitis. Moreover, studies providing a high
level of evidence on the management of associated CBDS
have also been published. Visualisation of CBDS by AUS is
a good predictor; patients with a high risk of CBDS should
have a pre-operative ERCP; patients with a moderate risk
should have non-invasive pre-operative investigation. How-
ever in both cases intra-operative exploration according to
the local expertise has been reported as a recommended
option with a high level of evidence. Furthermore we ob-
served lack of studies investigating the cost savings of trans-
cystic duct common bile duct removal of small stones.
The recommendations on the surgical treatment of
ACC are however limited to patients who may be good
candidates for urgent surgery. Grey areas still remain in
the cases of patients not fit for urgent surgery or for lap-
aroscopic surgery secondary to general conditions.
Diagnosis may be assessed by clinical, laboratory data
and AUS but with such a diagnostic approach results ap-
pear controversial and supported by a limited number of
high quality studies. A radiological investigation such
as HIDA may be required to reach a diagnostic cer-
tainty. Since symptomatic gallbladder stones are, in any
case, an indication for laparoscopic cholecystectomy,
the former diagnostic uncertainty may not be relevant
in healthy patients and the latter invasive radiological
investigation should therefore be applied only in high-
risk patients.
There is however no consensus on the evaluation of
the operative risk. These WSES guidelines define the pa-
tient condition in lieu of the cholecystitis severity score
as underlined in the TG13. This approach could favour a
tailored therapy on patient’s condition. Although the role
of percutaneous cholecystostomy after failed conserva-
tive treatment in those patients not fit for surgery sec-
ondary to severe co-morbidities has been reported, the
present guidelines have failed to find valuable criteria for
the definition of such high-risk patients. Data on criteria
for a definition of a high-risk patient other than that of
septic shock, are scarce and of poor level of evidence.
This is an area for research to improve the management
of patients with ACC.
According to some high quality studies, subtotal
cholecystectomy and low threshold for conversion
should be recommended in cases of severe acute in-
flammation of the gallbladder at operation. Although
the threshold for conversion strongly depends on the
experience and skills of the surgeon, we support the
development of an intraoperative score to help the
surgeon in the decision to complete the operation by
partial cholecystectomy and/or by open approach
when “the critical view of safety” cannot be reached
without adding risk.
Ansaloni et al. World Journal of Emergency Surgery  (2016) 11:25 Page 15 of 23
Appendix 1
Fig. 2 Vote results of statements
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Appendix 2
Table 5 WSES Guidelines statements
Topic # LoE GoR
Diagnosis 1.1 4 C There is no single clinical or laboratory finding with sufficient diagnostic accuracy to establish or exclude
acute cholecystitis. Combination of detailed history, complete clinical examination, and laboratory tests
may strongly support the diagnosis of ACC
1.2 2 B Abdominal ultrasound (AUS) is the preferred initial imaging technique for patients who are clinically
suspected to have ACC because of its lower cost, better availability, lack of invasiveness, and high
accuracy for gallbladder stones.
1.3 3 C exploration is a fairly reliable investigation method but its sensitivity and specificity for diagnosing ACC
may be relatively low according to the adopted AUS criteria.
1.4 2 B Evidence on the diagnostic accuracy of computed tomogram (CT) is scarce. While diagnostic accuracy of
magnetic resonance imaging (MRI) might be comparable to that of AUS, insufficient data are available to
support this. Hepatobiliary iminodiacetic acid scan (HIDA scan) has the highest sensitivity and specificity
for AC, although its scarce availability, long time required to perform the test, and exposure to ionizing
radiation limit its use.
1.5 4 C Combining clinical, laboratory and imaging investigations is recommended, although the best
combination is not yet known.
Treatment 2.1 2 B There is no role for gallstones dissolution, drugs or extra-corporeal shock wave lithotripsy (ESWL) or a
combination in the setting of ACC.
2.2 4 C Since there are no reports on surgical gallstone removal in the setting of ACC, surgery in the form of
cholecystectomy remains the main option
2.3 3 C Surgery is superior to observation of ACC in the clinical outcome and shows some cost-effectiveness
advantages due to the gallstone-related complications and to the high rate of readmission and surgery in
the observation group
2.4 2 C Antibiotics should be suggested as supportive care; they are effective in treating the first episode of ACC
but a high rate of relapse can be expected. Surgery is more effective than antibiotics alone in the
treatment of ACC.
2.5 3 C Cholecystectomy is the gold standard for treatment of ACC.
2.6 5 D If surgery is not available, medications such as antibiotics and analgesic should be prescribed and the
patients should be referred to a surgical center (depending upon the general condition) due to the high
rate of gallstone-related events.
Antibiotics 3.1 1 B Patients with uncomplicated cholecystitis can be treated without post-operative antibiotics when the
focus of infection is controlled by cholecystectomy
3.2 3 B In complicated cholecystitis, the antimicrobial regimens depend on presumed pathogens involved and
risk factors for major resistance patterns
3.3 3 C The results of microbiological analysis are helpful in designing targeted therapeutic strategies for
individual patients to customize antibiotic treatment and ensure adequate antimicrobial coverage in
patients with complicated cholecystitis and at high risk for antimicrobial resistance.
High risk patients 4.1 3 B Patient’s age above 80 in ACC is a risk factor for worse clinical behaviour, morbidity and mortality.
4.2 3 C The co-existence of diabetes mellitus does not contraindicate urgent surgery but must be re-considered
as a part of the overall patient comorbidity.
4.3 4 C Currently, there is no evidence of any scores in identifying patient’s risk in surgery for ACC. ASA, POSSUM
and APACHE II are correlated to surgical risk in patients with gallbladder perforation, higher accuracy
being for APACHE II. However, APACHE II is built to predict morbidity and mortality in the patients
admitted to ICU: its use as a preoperative score should be considered as an extension usage from the
original concept. Therefore, prospective and multicentre studies to compare different risk factors and
scores are necessary
Timing 5.1 1 A ELC is preferable to DLC in patients with ACC as long as it is completed within 10 days of onset of
symptoms.
5.2 2 B ELC should not be offered for patients beyond 10 days from the onset of symptoms unless symptoms
suggestive of worsening peritonitis or sepsis warrant an emergency surgical intervention. In people with
more than 10 days of symptoms, delaying cholecystectomy for 45 days is better than immediate surgery.
5.3 1 A ELC should be performed as soon as possible but can be performed up to 10 days of onset of
symptoms. However, it should be noted that earlier surgery is associated with shorter hospital stay and
fewer complications.
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Table 5 WSES Guidelines statements (Continued)
Type of surgery 6.1 2 B In ACC, a laparoscopic approach should initially be attempted except in case of absolute anaesthesiology
contraindications or septic shock.
6.2 1 A LC for ACC is safe, feasible, with a low complication rate and associated with shortened hospital stay.
6.3 3 C Among high-risk patients, in those with Child A and B cirrhosis, advanced age >80, or pregnant women,
laparoscopic cholecystectomy for ACC is feasible and safe.
6.4 3 A Laparoscopic or open subtotal cholecystectomy is a valid option for advanced inflammation, gangrenous
gallbladder, or any setting of the “difficult gallbladder” where anatomy is difficult to recognize and main
bile duct injuries are moe likely.
6.5 3 B In case of local severe inflammation, adhesions, bleeding in Calot’s triangle or suspected bile duct injury,
conversion to open surgery should be strongly considered.
Associated common bile
duct stones
7.1 2 B Elevation of liver biochemical enzymes and/or bilirubin levels are not sufficient to identify ACC patients
with choledocholithiasis and further diagnostic tests are needed.
7.2 1 A At AUS, the visualization of CBDS is a very strong predictor of choledocholithiasis. Indirect signs of stone
presence such as increased diameter of CBD are not sufficient to identify ACC patients with
choledocholithiasis and further diagnostic tests are needed.
7.3 2 B Liver biochemical tests, including ALT, AST bilirubin, ALP, gamma glutamyl transferase (GGT), AUS should
be performed in all patients with ACC to assess the risk for CBS.
7.4 5 D CBD stone risk should be stratified according to the proposed classification, modified from the American
Society of Gastrointestinal Endoscopy and the Society American of Gastrointestinal Endoscopic Surgeon
Guidelines.
7.5 1 A Patients with moderate risk for choledocholithiasis should undergo preoperative MRCP, EUS,
intraoperative cholangiography (IOC), or LUS depending on the local expertise and availability.
7.6 1 A with high risk for choledocholithiasis should undergo preoperative ERCP, IOC, LUS, depending on the
local expertise and the availability of the technique.
7.7 1 A CBDS could be removed preoperatively, intraoperatively, or postoperatively according to the local
expertise and the availability of the technique.
Alternative treatments 8.1 4 Gallbladder drainage, together with antibiotics, converts a septic cholecystitis into a non-septic condition;
however the level of evidence is poor.
8.2 4 C Among standardized gallbladder drainage techniques percutaneous transhepatic gallbladder drainage
(PTGBD) is generally recognized as the preferred technique due to the ease and the reduced costs.
8.3 2 B PC could be considered as a possible alternative to surgery after the failure of conservative treatment in a
small subset of patients unfit for emergency surgery due to their severe co-morbidities.
8.4 5 D DLC could be offered to patients after reduction of operative and anesthesiology- related risks to reduce
further hospitalization.
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